Roche announced that Actemra (tocilizumab) can significantly inhibit structura[1] damage to joints in patients with rheumatoid arthritis (RA), a critical measure of effectiveness of an RA treatment.
read more » Discuss Add this link to...Bury Add to:
| Bookmarks